Analyst firms · Wolfe Research · GH

Wolfe Research GH price target and rating history

Guardant Health Inc. (GH) · Health Care

Wolfe Research rates Guardant Health Inc. (GH) Outperform with a $150 price target, as of its latest action on Jun 2, 2026. It has published 3 rating actions on GH since December 2023, including 1 upgrade and 0 downgrades. Across 11 firms with a GH price target in the last 12 months, the median target is $165. Wolfe Research's $150 is 9% below that.

Current rating

Outperform

Price target

$150

Median target, all firms

$165

Actions on GH

3

Wolfe Research price target on GH

Every Wolfe Research rating on GH

• Jun 2, 2026
  ResumeWolfe Research resumes coverage at Outperform, price target $150
• Sep 25, 2025
  UpgradeWolfe Research upgrades to Outperform from Peer Perform, price target $75
• Dec 13, 2023
  InitiateWolfe Research starts coverage at Peer Perform

How other firms rate GH

Each firm's latest rating and stated target in the last 12 months.

Questions about Wolfe Research and GH

What is Wolfe Research's price target for GH?

Wolfe Research's latest stated price target for Guardant Health Inc. (GH) is $150, from its action on Jun 2, 2026.

What is Wolfe Research's rating on GH?

Wolfe Research rates GH Outperform, a bullish rating, as of Jun 2, 2026.

When did Wolfe Research last change its view on GH?

On Jun 2, 2026, Wolfe Research resumes coverage at Outperform, price target $150.

How does Wolfe Research's GH target compare with other analysts?

Across 11 firms with a GH price target in the last 12 months, the median target is $165. Wolfe Research's $150 is 9% below that.

More GH rating histories

• Morgan Stanley3
• Piper Sandler3
• Citigroup3

All Wolfe Research ratingsGH news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.